Sunshine Nuohe: STC007 Injection Solution Signs the "Technical License and Cooperative Development Agreement"

MetaMuskRat · 2026-03-22T08:27:55+00:00

Sunshine Nuohebio's wholly owned subsidiary, Nuohe Shengtai, has signed a cooperation agreement with Xinyi Tai to jointly develop the STC007 injection. Xinyi Tai has obtained exclusive rights for the Chinese market, while Nuohe Shengtai can receive a maximum upfront payment of 125 million yuan and milestone payments for research and development. After market approval, it can also receive sales milestone payments of up to 725 million yuan.

MetaMuskRat

2026-03-22 08:27:55

Abstract generation in progress

People’s Financial News, March 20 — Sunshine Nuohe (688621) announced on March 20 that its wholly-owned subsidiary Nuohe Shengtai recently reached a cooperation agreement and signed the corresponding “Technology Licensing and Cooperative Development Agreement” with Shenzhen Xinli Tai Pharmaceutical Co., Ltd. (hereinafter referred to as “Xinli Tai”) regarding the joint development of the STC007 injection project. According to the “Technology Licensing and Cooperative Development Agreement,” Xinli Tai will obtain exclusive licensing rights in China for the raw material drugs and formulation-related intellectual property rights and licensed technology for all pruritus indications, including but not limited to product research and development, registration, production, and commercialization. Nuohe Shengtai will receive a total of up to 125 million yuan in upfront and milestone payments for research and development. If the product is approved for market sale and the net sales (measured by calendar year) first reach the agreed amount, Nuohe Shengtai will receive sales milestone payments, with a maximum total of 725 million yuan in sales milestones.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes